Viela Bio a clinical-stage biotechnology company focused on treatments for autoimmune and inflammatory diseases. Co.'s pipeline includes nebilizumab, which Co. is developing as a potential first-line monotherapy for neuromyelitis optica spectrum disorder, VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and other binding partners; and VIB7734, which is a humanized monoclonal antibody (mAb) intended to be a treatment for autoimmune diseases. Co. is also conducting pre-clinical research and development on two product candidates including VIB1116, which is a mAb and a mAb cytokine fusion protein. We show 7 historical shares outstanding datapoints in our coverage of VIE's shares outstanding history.
Understanding the changing numbers of VIE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VIE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VIE by allowing them to research VIE shares outstanding history
as well as any other stock in our coverage universe. |
Free VIE Email Alerts:
Video: Shares Outstanding Importance
